# Inflammatix, Inc.

> Inflammatix is a Sunnyvale, California molecular diagnostics company that reads the body's own immune response instead of hunting for the pathogen. Its FDA-cleared TriVerity test measures 29 host mRNAs from a blood sample and, using machine-learning algorithms, returns three scores in about 30 minutes: likelihood of bacterial infection, likelihood of viral infection, and overall illness severity. Run on the company's benchtop Myrna instrument, it is built for emergency and critical-care clinicians who need to decide fast whether a patient is heading toward sepsis. Spun out of Stanford in 2016, the company has raised more than $205M.

- **Founded:** 2016
- **Headquarters:** Sunnyvale, California, United States
- **Founders:** Tim Sweeney (Co-Founder & CEO), Purvesh Khatri (Co-Founder & Chief Scientist), Jonathan Romanowsky (Co-Founder & Board Member)
- **Team size:** ~74 employees
- **Products:** TriVerity Acute Infection and Sepsis Test, Myrna Instrument, Host-response pipeline (InSep, ViraBac EZ)
- **Notable:** FDA clearance for the first-in-class TriVerity Acute Infection and Sepsis Test System (January 2025)., FDA Breakthrough Device Designation for TriVerity (November 2023); only about 10% of such designations reach clearance., SEPSIS-SHIELD pivotal study across 1,222 patients at 22 sites showed high diagnostic and prognostic accuracy regardless of immune status or race, with a roughly 0.5% false-negative rate.

## Products & services

- **TriVerity Acute Infection and Sepsis Test** — A first-in-class molecular blood test that reads 29 host mRNAs and uses machine-learning algorithms to return three results in about 30 minutes: likelihood of bacterial infection, likelihood of viral infection, and all-cause illness severity (risk of needing mechanical ventilation, vasopressors, or renal replacement within 7 days). FDA-cleared in January 2025.
- **Myrna Instrument** — A benchtop, sample-to-answer, cartridge-based point-of-care platform that runs TriVerity using isothermal RT-LAMP chemistry, designed for emergency departments and critical-care settings.
- **Host-response pipeline (InSep, ViraBac EZ)** — Earlier and pipeline branding for the company's host-response acute infection and bacterial-vs-viral tests, including a BARDA-funded ViraBac EZ program.

## Achievements

- FDA clearance for the first-in-class TriVerity Acute Infection and Sepsis Test System (January 2025).
- FDA Breakthrough Device Designation for TriVerity (November 2023); only about 10% of such designations reach clearance.
- SEPSIS-SHIELD pivotal study across 1,222 patients at 22 sites showed high diagnostic and prognostic accuracy regardless of immune status or race, with a roughly 0.5% false-negative rate.
- Raised more than $205M in private capital plus more than $50M in grants and contracts.
- Published analytical validation of TriVerity on the Myrna instrument in the Journal of Clinical Microbiology (2025).
- Selected by the U.S. military for early deployment of its test system.

## Latest updates

- **2024-09** — Closed a $57M Series E led by Khosla Ventures and Think.Health to advance TriVerity toward commercialization.
- **2025-01** — Received FDA clearance for the first-in-class TriVerity Test System.
- **2025-02** — Stanford Medicine published a feature on the test and the science behind it.
- **2025-03** — Shipped TriVerity cartridges and Myrna instruments to the U.S. military (JPEO-CBRND).
- **2025-05** — Analytical validation of TriVerity on the Myrna instrument published in the Journal of Clinical Microbiology.

## Links

- Website: https://inflammatix.com
- LinkedIn: https://www.linkedin.com/company/inflammatix
- Twitter/X: https://twitter.com/inflammatix_inc

---

Profile page: https://yespress.io/inflammatix-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-14